A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Exclusion Criteria

• •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies).
• •Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).
• •A positive urine drug screen for drugs of abuse or recreational drugs.
• •Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results.
• •History of abuse of alcohol or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
• •Current smokers and those who have smoked any substance within the last 12 months.
• •Treatment with an investigational drug within 1 month preceding the first dose of study medication.
• •Have participated in any clinical study with exposure to 14\^C in the last 12 months.
• •Any radiation exposure, including that which is projected to result from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures. No occupationally exposed worker, as defined in the Ionising Radiation Regulation 1999, shall participate in the study.
• •Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days prior to the first dose of study medication.
• •Use of herbal supplements within 28 days prior to the first dose of study medication.
• •Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
• •Participants who have previously participated in a clinical trial for ertugliflozin.
• •Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.